We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population. We developed a ...
Nipple Fluid Carcinoembryonic Antigen and Prostate-Specific Antigen in Cancer-Bearing and Tumor-Free Breasts PURPOSE: In node-negative patients, of whom up to 30% will recur within 5 years after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results